A Principal Investigator (PI) working for Rutgers New Jersey Medical School at Rutgers University was appointed to the Moderna COVID-19 vaccine study, testing the investigational vaccine known as mRNA-1273. A new kind of vaccine, mRNA-1273 is developed with messenger-RNA-based life science technology: as is Pfizer and BioNTech’s BNT162b2 and an investigational candidate from Germany-based Curevac. Recently, Dr. Shobha Swaminathan, an associate professor at Rutgers New Jersey Medical School and medical director of infectious diseases practice at University Hospital took the time recently for an interview concerning the novel vaccine candidate.
Recently, Tom Bergeron writing for a local online news media called ROI NJ was able to secure time with the busy investigator. An important milestone was met recently, showcased in the news by Moderna and collaborator National Institute of Allergy and Infectious Diseases (NIAID): the mRNA-1273 vaccine candidate had a efficacy rate of 94.5% thus far after interim analysis.
As Dr. Swaminathan has participated in an number of vaccine trials—including two times the opportunity to serve as the PI—she shares some insights with the reader. Importantly, although there were early rumblings of concerns in the African American community in inner-city New Jersey (e.g. Newark, Jersey City Trenton, etc.), the study team nationwide was able to enroll a diversified volunteer population.
Shobha Swaminathan, MD, an associate professor at Rutgers New Jersey Medical School and medical director of infectious diseases practice at University Hospital
Call to Action: Visit ROI NJ to read the entire interview authored by Mr. Bergeron.